OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records
Yan Xie, Benjamin Bowe, Hong Xian, et al.
The Lancet Diabetes & Endocrinology (2023) Vol. 11, Iss. 9, pp. 644-656
Closed Access | Times Cited: 40
Yan Xie, Benjamin Bowe, Hong Xian, et al.
The Lancet Diabetes & Endocrinology (2023) Vol. 11, Iss. 9, pp. 644-656
Closed Access | Times Cited: 40
Showing 1-25 of 40 citing articles:
Causal machine learning for predicting treatment outcomes
Stefan Feuerriegel, Dennis Frauen, Valentyn Melnychuk, et al.
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 958-968
Closed Access | Times Cited: 54
Stefan Feuerriegel, Dennis Frauen, Valentyn Melnychuk, et al.
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 958-968
Closed Access | Times Cited: 54
Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents
Jingqian Su, Yingsheng Luo, Shan Hu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13381-13381
Open Access | Times Cited: 45
Jingqian Su, Yingsheng Luo, Shan Hu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13381-13381
Open Access | Times Cited: 45
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Maximilian Huttasch, Michael Roden, S. Kahl
Metabolism (2024) Vol. 157, pp. 155937-155937
Open Access | Times Cited: 34
Maximilian Huttasch, Michael Roden, S. Kahl
Metabolism (2024) Vol. 157, pp. 155937-155937
Open Access | Times Cited: 34
12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study
Riccardo De Giorgi, Ivan Koychev, Amanda Adler, et al.
EClinicalMedicine (2024) Vol. 74, pp. 102726-102726
Open Access | Times Cited: 17
Riccardo De Giorgi, Ivan Koychev, Amanda Adler, et al.
EClinicalMedicine (2024) Vol. 74, pp. 102726-102726
Open Access | Times Cited: 17
Mapping the effectiveness and risks of GLP-1 receptor agonists
Yan Xie, Taeyoung Choi, Ziyad Al‐Aly
Nature Medicine (2025)
Closed Access | Times Cited: 15
Yan Xie, Taeyoung Choi, Ziyad Al‐Aly
Nature Medicine (2025)
Closed Access | Times Cited: 15
The benefits of GLP1 receptors in cardiovascular diseases
L. Pojskic, Denis Mršić, Amra Macić-Džanković
Frontiers in Clinical Diabetes and Healthcare (2023) Vol. 4
Open Access | Times Cited: 41
L. Pojskic, Denis Mršić, Amra Macić-Džanković
Frontiers in Clinical Diabetes and Healthcare (2023) Vol. 4
Open Access | Times Cited: 41
Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data
Patrick Bidulka, David G. Lugo‐Palacios, Orlagh Carroll, et al.
BMJ (2024), pp. e077097-e077097
Open Access | Times Cited: 13
Patrick Bidulka, David G. Lugo‐Palacios, Orlagh Carroll, et al.
BMJ (2024), pp. e077097-e077097
Open Access | Times Cited: 13
Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes
Riccardo Candido, Sara Gaiotti, Fabiola Giudici, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 18, pp. 6052-6052
Open Access | Times Cited: 17
Riccardo Candido, Sara Gaiotti, Fabiola Giudici, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 18, pp. 6052-6052
Open Access | Times Cited: 17
Emerging role of antidiabetic drugs in cardiorenal protection
Wen-Jia Fu, Jin-Ling Huo, Zi‐Hui Mao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7
Wen-Jia Fu, Jin-Ling Huo, Zi‐Hui Mao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7
Heterogeneous treatment effects of sodium‐glucose cotransporter 2 inhibitors on risk of dementia in people with type 2 diabetes: A population‐based cohort study
Huilin Tang, William T. Donahoo, Mikael Svensson, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5528-5539
Open Access | Times Cited: 7
Huilin Tang, William T. Donahoo, Mikael Svensson, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5528-5539
Open Access | Times Cited: 7
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes
Daniel Edmonston, Hillary Mulder, Elizabeth Lydon, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 8, pp. 696-708
Closed Access | Times Cited: 6
Daniel Edmonston, Hillary Mulder, Elizabeth Lydon, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 8, pp. 696-708
Closed Access | Times Cited: 6
Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study
Fei‐Yuan Hsiao, Elise Tan, Lin-Chieh Meng, et al.
The Lancet Healthy Longevity (2024), pp. 100621-100621
Open Access | Times Cited: 6
Fei‐Yuan Hsiao, Elise Tan, Lin-Chieh Meng, et al.
The Lancet Healthy Longevity (2024), pp. 100621-100621
Open Access | Times Cited: 6
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes
Rohan Khera, Arya Aminorroaya, Lovedeep S Dhingra, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 10, pp. 904-917
Closed Access | Times Cited: 5
Rohan Khera, Arya Aminorroaya, Lovedeep S Dhingra, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 10, pp. 904-917
Closed Access | Times Cited: 5
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
André Scheen
Diabetes & Metabolism (2023) Vol. 49, Iss. 5, pp. 101474-101474
Closed Access | Times Cited: 11
André Scheen
Diabetes & Metabolism (2023) Vol. 49, Iss. 5, pp. 101474-101474
Closed Access | Times Cited: 11
Unlocking the broad health benefits and risks of GLP-1 receptor agonist drugs
Nature Medicine (2025)
Closed Access
Nature Medicine (2025)
Closed Access
Exploring hypertension-linked diseases: a comprehensive review of innovative drug combinations with enhanced therapeutic potential
Bhavesh Thakkar, Hetvi Dadhaniya, Kiran Dudhat
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Bhavesh Thakkar, Hetvi Dadhaniya, Kiran Dudhat
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Advances in energy balance & metabolism circuitry
José G. Grajales-Reyes
Advances in genetics (2025)
Closed Access
José G. Grajales-Reyes
Advances in genetics (2025)
Closed Access
Antidiabetic Drugs Consumption in France Over a Decade: An Observational Study
David De Bandt, Johanna Mezence, Claire Lange, et al.
Clinical Therapeutics (2025)
Open Access
David De Bandt, Johanna Mezence, Claire Lange, et al.
Clinical Therapeutics (2025)
Open Access
Comparative cardiovascular effectiveness of newer glucose-lowering drugs in elderly with type 2 diabetes: a target trial emulation cohort study
Vanja Kosjerina, Mojtaba Parsa, Stine H. Scheuer, et al.
EClinicalMedicine (2025) Vol. 82, pp. 103162-103162
Closed Access
Vanja Kosjerina, Mojtaba Parsa, Stine H. Scheuer, et al.
EClinicalMedicine (2025) Vol. 82, pp. 103162-103162
Closed Access
Incretin-based therapies: advancements, challenges, and future directions in type 2 diabetes management
Amruth Akhil Alluri, Yashaswi Guntupalli, Shruti Suresh Suvarna, et al.
Journal of Basic and Clinical Physiology and Pharmacology (2025)
Closed Access
Amruth Akhil Alluri, Yashaswi Guntupalli, Shruti Suresh Suvarna, et al.
Journal of Basic and Clinical Physiology and Pharmacology (2025)
Closed Access
Paeoniflorin: a review of its pharmacology, pharmacokinetics and toxicity in diabetes
Xue Ou, Zhijie Yu, Chun Pan, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Xue Ou, Zhijie Yu, Chun Pan, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study
Yu‐Nan Huang, Wen‐Ling Liao, Jing‐Yang Huang, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 11, pp. 5222-5232
Closed Access | Times Cited: 3
Yu‐Nan Huang, Wen‐Ling Liao, Jing‐Yang Huang, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 11, pp. 5222-5232
Closed Access | Times Cited: 3
Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM Study
Rohan Khera, Arya Aminorroaya, Lovedeep S Dhingra, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Rohan Khera, Arya Aminorroaya, Lovedeep S Dhingra, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Making causal inferences from transactional data: A narrative review of opportunities and challenges when implementing the target trial framework
Santiago Esteban, Alejandro G. Szmulewicz
Journal of International Medical Research (2024) Vol. 52, Iss. 3
Open Access | Times Cited: 1
Santiago Esteban, Alejandro G. Szmulewicz
Journal of International Medical Research (2024) Vol. 52, Iss. 3
Open Access | Times Cited: 1
Adverse cardiovascular and kidney outcomes in people with SARS-CoV-2 treated with SGLT2 inhibitors
Taeyoung Choi, Yan Xie, Ziyad Al‐Aly
Communications Medicine (2024) Vol. 4, Iss. 1
Open Access | Times Cited: 1
Taeyoung Choi, Yan Xie, Ziyad Al‐Aly
Communications Medicine (2024) Vol. 4, Iss. 1
Open Access | Times Cited: 1
